Husseini Manji, M.D., global head of neuroscience at Janssen Research & Development, LLC, has pioneered a ketamine-based nasal spray that has swiftly alleviated depressive symptoms in patients who have not responded to other medications. Dr. Manji is a former NIMH fellow, lab chief and director of NIH’s Mood and Anxiety Disorders Program.
Study details: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5838571/
Free ebook from Understanding Depression: actifypress.com/depression
Please become a Patron: patreon.com/actifypress
Sign up for our Morning Buzz Newsletter: actifypress.com/buzz
Support Actify on Social Media:
Originally posted by Actify Press on 2019-06-11 03:12:17